# Assessing the Safety and Efficacy of the LAmbre™ Plus Device

Study · id `cardio:ct-nct06465706` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06465706](<https://clinicaltrials.gov/study/NCT06465706>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06465706

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1826 participants.

## Technical summary

Registry record NCT06465706. Randomized; single masking; primary purpose treatment. Start 2024-09-01 (anticipated); primary completion 2029-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1826 participants (planned count; ClinicalTrials.gov record NCT06465706, source copy `cardio:ctgov-nct06465706-2024-08-23`, retrieved 2026-10-26)
- Planned start: 2024-09-01 (anticipated) (ClinicalTrials.gov record NCT06465706, source copy `cardio:ctgov-nct06465706-2024-08-23`, retrieved 2026-10-26)
- Primary completion: 2029-10-01 (anticipated) (ClinicalTrials.gov record NCT06465706, source copy `cardio:ctgov-nct06465706-2024-08-23`, retrieved 2026-10-26)
- Completion: 2030-01-31 (anticipated) (ClinicalTrials.gov record NCT06465706, source copy `cardio:ctgov-nct06465706-2024-08-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06465706-2024-08-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessing the Safety and Efficacy of the LAmbre™ Plus Device
- Acronym: REDUCE-AF
- Condition: Atrial Fibrillation
- Intervention (Device): LAmbre investigational device
- Lead sponsor: Kansas City Heart Rhythm Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Kansas City Heart Rhythm Research Foundation (`cardio:org-kansas-city-heart-rhythm-research-foundation`)

## Provenance

Content hash: 2dcc8d9221a220f2bcd8ead9f239fc0d156658a6ddcc344182bb792752240ade
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
